Pseudo type III dyslipoproteinemia is associated with normal fibroblast lipoprotein receptor activity

被引:3
作者
Giroux, LM
Cohn, JS
LaMarre, J
Davignon, J
机构
[1] CLIN RES INST MONTREAL,HYPERLIPIDEMIA & ATHEROSCLEROSIS RES GRP,QUEBEC CITY,PQ H2W 1R7,CANADA
[2] UNIV GUELPH,DEPT BIOMED SCI,GUELPH,ON N1G 2W1,CANADA
基金
英国医学研究理事会;
关键词
pseudo type III dyslipoproteinemia; low-density lipoprotein receptor; lipoprotein receptor-related protein; lipolysis-stimulated receptor;
D O I
10.1016/S0021-9150(97)00072-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pseudo type III (PT-III) dyslipoproteinemia is characterized by a plasma accumulation of triglyceride-rich lipoproteins (TRL) and their remnants. It mimics type III, but its etiology can not be ascribed to a genetic apo E defect. In order to determine whether PT-III is associated with a genetic lipoprotein receptor abnormality, we have measured (in cultured fibroblasts from affected and nonaffected individuals) the in vitro activity of three lipoprotein receptors which are implicated in the catabolism of TRL, namely the low-density lipoprotein receptor (LDL-R), the lipoprotein receptor-related protein (LRP) and the lipolysis-stimulated receptor (LSR). Specific cell association and degradation of I-125-LDL by LDL-R-upregulated PT-III fibroblasts was not significantly different from that of control cells (103 +/- 10% and 98 +/- 17% of controls; 20 mu g/ml I-125-LDL). Specific cell association and degradation of rabbit I-125-beta-VLDL was also not significantly different. LRP activity was assessed by measuring the ability of PT-III and control cells to bind three different LRP ligands: activated alpha(2)-macroglobulin (alpha(2)M-MA), lactoferrin and apo E-enriched rabbit beta-VLDL. No significant differences were observed (24.0 +/- 2.1 vs. 23.4 +/- 5.7 fmol/mg for 5 nM of I-125-alpha(2),M-MA; 4.8 +/- 0.3 vs. 5.2 +/- 1.3 mu g/mg for 20 mu g/ml of I-125-lactoferrin; 319.4 +/- 51.2 vs. 309.5 +/- 23.2 ng/mg for 5 mu g/ml of I-125-beta-VLDL, PT-III vs. control, respectively). LSR activity, as assessed by the cell association or degradation of I-125-LDL by fibroblasts in the presence of 0.5 mM oleate and human leptin, was also not different. No evidence was obtained for deficient cellular recognition of PT-III TRL (d < 1.006 g/ml) by normal human fibroblasts or mouse macrophages. These results suggest that PT-III dyslipoproteinemia is not due to an accumulation in plasma of poorly recognized TRL, nor due to a genetic defect in LDL-R, LRP or LSR. (C) 1997 Elsevier Science Ireland Ltd.
引用
收藏
页码:85 / 94
页数:10
相关论文
共 40 条
[1]  
ALLAIN CC, 1974, CLIN CHEM, V20, P470
[2]   FREE FATTY-ACIDS ACTIVATE A HIGH-AFFINITY SATURABLE PATHWAY FOR DEGRADATION OF LOW-DENSITY LIPOPROTEINS IN FIBROBLASTS FROM A SUBJECT HOMOZYGOUS FOR FAMILIAL HYPERCHOLESTEROLEMIA [J].
BIHAIN, BE ;
YEN, FT .
BIOCHEMISTRY, 1992, 31 (19) :4628-4636
[3]  
BIHAIN BE, 1995, DIABETES METAB, V21, P121
[4]  
BIHAIN BE, 1995, ATHEROSCLEROSIS, V10, P465
[5]  
BROWN MS, 1986, SCIENCE, V232, P3447
[6]  
CHOI SY, 1993, J BIOL CHEM, V268, P15804
[7]   A PHENOCOPY OF TYPE-III DYSBETALIPOPROTEINEMIA OCCURRING IN A CANDIDATE FAMILY FOR A PUTATIVE APO-E RECEPTOR DEFECT [J].
DAVIGNON, J ;
DALLONGEVILLE, J ;
ROEDERER, G ;
ROY, M ;
FRUCHART, JC ;
KESSLING, AM ;
BOUTHILLIER, D ;
LUSSIERCACAN, S .
ANNALS OF MEDICINE, 1991, 23 (02) :161-167
[8]  
DAVIGNON J, 1992, P 9 INT S ATH, P199
[9]  
deFaria E, 1996, J LIPID RES, V37, P197
[10]  
GIANTURCO SH, 1994, J LIPID RES, V35, P1674